Montelukast Heumann (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Heumann, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients who require long‑term control of airway inflammation.

GNH USA supplies Montelukast Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used in respiratory and allergic disease management.

- Asthma: reduces the frequency and severity of bronchospasm episodes. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, suicidal thoughts, or agitation. - Stevens‑Johnson syndrome: severe skin eruption. - Hepatic injury: elevated liver enzymes or hepatitis.

Montelukast should be used with appropriate clinical oversight.

- Assess liver function: monitor hepatic enzymes in patients with liver disease. - Evaluate psychiatric history: observe for mood alterations or suicidal ideation. - Use caution in severe asthma: not a rescue medication for acute attacks. - Avoid during acute asthma exacerbations: ensure alternative rescue therapy is available. - Store at room temperature: keep in the original container, protect from moisture and heat.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism, lowering montelukast levels. - Phenobarbital: induces metabolism, reducing therapeutic effect. - St. John's Wort: enzyme induction may decrease drug exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask bronchospasm symptoms. - ACE inhibitors: possible additive respiratory effects. - NSAIDs: may increase risk of bronchospasm in sensitive individuals.